Cheng Shi-Yann, Ming Ho, Lee Jui-Chi
Department of Obstetrics, China Medical University Beigang, Hospital, Beigang, Yunlin, China.
Obstet Gynecol. 2008 Jan;111(1):119-25. doi: 10.1097/01.AOG.0000297313.68644.71.
To compare the efficacy and safety of titrated oral misoprostol and vaginal misoprostol for labor induction.
Women between 34 and 42 weeks of gestation with an unfavorable cervix (Bishop score less than or equal to 6) and an indication for labor induction were randomLy assigned to receive titrated oral or vaginal misoprostol. The titrated oral misoprostol group received a basal unit of 20 mL misoprostol solution (1 mcg/mL) every 1 hour for four doses and then were titrated against individual uterine response. The vaginal group received 25 mcg every 4 hours until attaining a more favorable cervix. Vaginal delivery within 12 hours was the primary outcome. The data were analyzed by intention-to-treat.
Titrated oral misoprostol was given to 101 (48.8%) women and vaginal misoprostol to 106 (51.2%) women. Completed vaginal delivery occurred within 12 hours in 75 (74.3%) women in the titrated oral group and 27 (25.5%) women in the vaginal group (relative risk [RR] 8.44, 95% confidence interval [CI] 4.52-15.76). The incidence of hyperstimulation was 0.0% in the titrated oral group compared with 11.3% in the vaginal group (RR 0.08, 95% CI 0.01-0.61). Although more women experienced nausea (10.9%) in the titrated oral group (RR 27.07, 95% CI 1.57-465.70), fewer infants had Apgar scores of less than 7 at 1 minute in the titrated oral group than in the vaginal group (RR 0.10, 95% CI 0.01-0.76).
Titrated oral misoprostol is associated with a lower incidence of uterine hyperstimulation and a lower cesarean delivery rate than vaginal misoprostol for labor induction in patients with unfavorable cervix.
ClinicalTrials.gov, www.clinicaltrials.gov, NCT00529295
I.
比较滴定剂量口服米索前列醇与阴道用米索前列醇引产的有效性和安全性。
将妊娠34至42周、宫颈条件不佳( Bishop评分小于或等于6分)且有引产指征的妇女随机分配接受滴定剂量口服或阴道用米索前列醇。滴定剂量口服米索前列醇组每1小时接受20 mL米索前列醇溶液(1 mcg/mL)的基础剂量,共4剂,然后根据个体子宫反应进行滴定。阴道组每4小时接受25 mcg,直至宫颈条件改善。12小时内阴道分娩是主要结局。数据采用意向性分析。
101名(48.8%)妇女接受滴定剂量口服米索前列醇,106名(51.2%)妇女接受阴道用米索前列醇。滴定剂量口服组75名(74.3%)妇女在12小时内完成阴道分娩,阴道组27名(25.5%)妇女完成阴道分娩(相对危险度[RR] 8.44,95%置信区间[CI] 4.52 - 15.76)。滴定剂量口服组子宫过度刺激发生率为0.0%,而阴道组为11.3%(RR 0.08,95% CI 0.01 - 0.61)。虽然滴定剂量口服组更多妇女出现恶心(10.9%)(RR 27.07,95% CI 1.57 - 465.70),但滴定剂量口服组1分钟时Apgar评分低于7分的婴儿少于阴道组(RR 0.10,95% CI 0.01 - 0.76)。
对于宫颈条件不佳的患者引产,滴定剂量口服米索前列醇与阴道用米索前列醇相比,子宫过度刺激发生率更低,剖宫产率也更低。
ClinicalTrials.gov,www.clinicaltrials.gov,NCT00529295
I级